Company ProfilePremium

Mylan N.V.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Mylan N.V. - Healthcare showcase

Year Founded & Workforce

1961

35,000 Employees

Industry

Healthcare

Services

PrillsPulmonary Arterial HypertensionAnticholinergicAutoinjectorInfluenza Vaccine
M

Mylan N.V. Employee Contacts

6 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Mylan N.V. Overview

Company Overview

Company Headquarters: Pennsylvania, US

Founded: 1961

Workforce: 35,000+

Company Working: Mylan N.V. (Mylan) is a leading global pharmaceutical company. The company develops, licenses, manufactures, markets, and distributes generics, branded generics, brand name, and over-the-counter (OTC) products in a variety of dosage forms and therapeutic categories. Its global portfolio constitutes more than 7,500 marketed generic and branded generic brand names and OTC products around the world covering a vast array of therapeutic categories. Mylan’s team works in various offices and manufacturing facilities across the world. It has global centers in Bangalore, India; Canonsburg, Pennsylvania; and Dublin, Ireland. Its global research and development (R&D) centers are situated in Hyderabad, India, and Morgantown, West Virginia. It also has 12 technology-focused R&D sites across Europe, India, Japan, and the US. It adheres to the highest quality standards across its 50 manufacturing facilities worldwide

Strategy

Mylan N.V. aims at setting new standards in healthcare by creating better health for its customers. It also aims to strengthen its position in the market by carrying out various collaborations and partnerships. The constant financial growth of the company in recent years is assisting in gaining competitive advantage. Reducing R&D expenditure is a part of the cost-cutting approach which is hampering research and development activities.

Company Snapshot

$9,429.3M

Revenue

35,000

Employees

$21,200M

Market Cap

1961

Founded

Pennsylvania, US

Headquarters

SWOT Analysis

Strengths

  • Robust worldwide commercial presence
  • Offers an extensive range of dosage forms and delivery systems
  • Involved in mergers and acquisitions
  • Worldwide commercial presence
  • Diverse product portfolio
  • Strong global presence
  • Robust worldwide commercial presence Offers an extensive range of dosage forms and delivery systems Involved in mergers and acquisitions

Weaknesses

  • Limited number of products
  • Dependency on local markets for revenue generation
  • Brand image hampered due to alleged litigations

Opportunities

  • Collaborations to develop innovative medicines
  • Worldwide expansion through mergers and acquisitions

Threats

  • Pricing pressures may affect the company's future revenues
  • Intense competition

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
March 2018AcquisitionMylan acquired Meda AB, thus, expanding its franchise in various therapeutic areas.
March 2018AcquisitionMylan completed the acquisition of Meda, thus, expanding its franchises in various therapeutic areas.
December 2016Product LaunchMylan launched the generic for EpiPen Autoinjector at a 50% lower price than the patented EpiPen.

Product Offering

  • Mylan N.V.
    • Prills
    • Pulmonary Arterial Hypertension
    • Anticholinergic
    • Autoinjector
    • Influenza Vaccine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 9,429.3 Mn in 2015 to USD 11,907.7 Mn in 2017.
Mylan N.V. — By Business Segment
Series (USD Mn)201520162017
Sales9,429.311,076.911,907.7
R&D Expenditure671.9826.8783.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.